CD19 and acute lymphoblastic leukemia: Two clinical trials testing haploidentical donor-derived CAR NK cells for targeting of refractory CD19+ ALL with a second-generation anti-CD19 CAR that incorporates the 4-1BB costimulatory domain are currently recruiting patients (NCT00995137 from St.